Drug intelligence / Profile preview

NRTUA

Development stage: Preclinical
Modality: Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics

Overview

NRTUA is an attenuated strain of *Toxoplasma gondii* being investigated for its anti-tumor efficacy, particularly in combination with anti-PD-1 antibodies. It functions by altering the tumor microenvironment, which leads to increased infiltration of CD8+ T cells and tumor-specific IFN-γ production, mediated by dendritic cell-secreted IL-12. This mechanism aims to enhance the immune system's ability to fight cancer.

Other names: attenuated Toxoplasma gondii NRTUAattenuated T. gondii NRTUA

Beyond the preview

Go deeper on NRTUA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRTUA.